biostudies-literaturePan DNIAID NIH HHSNHLBI NIH HHSNCI NIH HHSNINDS NIH HHS9168-71https://www.ebi.ac.uk/biostudies/studies/S-EPMC3124378biostudies-literatureUnknown133(24)A new site-targeted molecular imaging contrast agent based on a nanocolloidal suspension of lipid-encapsulated, organically soluble divalent copper has been developed. Concentrating a high payload of divalent copper ions per nanoparticle, this agent provides a high per-particle r1 relaxivity, allowing sensitive detection in T1-weighted magnetic resonance imaging when targeted to fibrin clots in vitro. The particle also exhibits a defined clearance and safety profile in vivo.Journal of the American Chemical SocietySynthesis of NanoQ, a copper-based contrast agent for high-resolution magnetic resonance imaging characterization of human thrombus.PMC3124378R01 NS059302-05R01 HL073646-07HL073646R01 HL073646R01 NS059302CA119342NS059302U54 CA119342N01CO37007Yalaz CMarsh JNPan DCaruthers SDSenpan AStacy AJHu GWickline SALanza GMGaffney PJfalseSynthesis of NanoQ, a copper-based contrast agent for high-resolution magnetic resonance imaging characterization of human thrombus.A new site-targeted molecular imaging contrast agent based on a nanocolloidal suspension of lipid-encapsulated, organically soluble divalent copper has been developed. Concentrating a high payload of divalent copper ions per nanoparticle, this agent provides a high per-particle r1 relaxivity, allowing sensitive detection in T1-weighted magnetic resonance imaging when targeted to fibrin clots in vitro. The particle also exhibits a defined clearance and safety profile in vivo.2011-01-01T00:00:00Z2011 Jun2025-04-04T21:58:29.956Z2019-03-27T00:43:03ZS-EPMC31243782159903010.1021/ja201918u